Amicus Therapeutics (FOLD) Soars 10.05% on Japan Approval
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jul 17, 2025 6:48 am ET1min read
FOLD--
Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported that it received approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of Pompe disease in Japan, which has led to a 10.05% rise in pre-market trading on July 17, 2025.
Amicus Therapeutics has adjusted its 2025 total revenue growth guidance to 15-22% and lowered expectations for Pombiliti + Opfolda growth. The company also reiterated its commitment to advancing its pipeline and expanding its commercial footprint.
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet